医学
表皮生长因子受体
背景(考古学)
肺癌
克拉斯
普通合伙企业
表皮生长因子受体抑制剂
个性化
肿瘤科
精密医学
癌症
重症监护医学
内科学
生物信息学
病理
生物
古生物学
结直肠癌
经济
财务
万维网
计算机科学
作者
Andrew J. Piper-Valillo,Hollis Viray,Jill Feldman,Deepa Rangachari
摘要
The Oncology Grand Rounds series is designed to place original reports published in the Journal into clinical context. A case presentation is followed by a description of diagnostic and management challenges, a review of the relevant literature, and a summary of the authors’ suggested management approaches. The goal of this series is to help readers better understand how to apply the results of key studies, including those published in Journal of Clinical Oncology , to patients seen in their own clinical practice. Patients with epidermal growth factor receptor ( EGFR)–mutated advanced non–small-cell lung cancer represent a distinct subgroup of individuals who can experience initially tolerable and durable effects with first-line EGFR-directed tyrosine kinase inhibitors. Unfortunately, acquired treatment resistance and cancer progression within the CNS are inevitable during the disease course and present a challenging transition in the care continuum. Next-line therapies generally require combinations of drugs and afford nuanced differences in clinical outcomes relative to the treatment experience, toxicity profile, and quality of life. Therapeutic stratification and modulation thus require further personalization and partnership with patients to identify key clinical, molecular, and human-specific factors to best guide optimal care.
科研通智能强力驱动
Strongly Powered by AbleSci AI